Tests treatments for high-risk medulloblastoma, a type of brain tumor, in patients over 3
Compares radiotherapy schedules and maintenance chemotherapy in high-risk medulloblastoma patients.
Key facts
- Who runs it
- The University Of Birmingham
- Where
- Aarhus N, Copenhagen Oe, and Odense C, DenmarkSee the 3 sitesAlso in 10 other countries, 95 sites
- Trial code
- EU 2024-510578-25-00
- EudraCT 2018-004250-17
- ISRCTN16314648
- Registry title
- SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 311 people, planned
- Started
- 5 Nov 2021
- Expected to end
- 1 Apr 2032
- Type of study
- Interventional
- Record updated
- 4 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, young people and adults aged 3 years or older with newly diagnosed high-risk medulloblastoma, confirmed under the microscope, who have had no treatment other than surgery.
- Age
- From 3 years at diagnosis up to 64 years.
- Sex
- All sexes can join.
- Disease stage
- High-risk medulloblastoma of the SHH group or the non-SHH/non-WNT groups (Groups 3 and 4), with at least one extra high-risk feature, such as spread of the disease, large cell/anaplastic type, MYC or MYCN amplified tumour, SHH-TP53 mutant tumour, or significant leftover tumour (> 1.5 cm2) after surgery.
- Earlier treatment
- No treatment for medulloblastoma before the trial except surgery. One cycle of carboplatin and etoposide is allowed if treatment must start urgently.
- Biomarker or test result
- Tumour biology must be SHH or non-SHH/non-WNT (Groups 3 and 4). Tumour and blood samples must be sent for molecular tests.
Main reasons for not taking part
- Proven or likely germline TP53, APC, PTCH1, SUFU, PALB2 or BRCA2 gene change, or another DNA repair defect
- Pregnant or breastfeeding women
- WNT medulloblastoma with a CTNNB1 mutation
- Chang Stage M4 disease
- Earlier treatment for a brain tumour or any other cancer
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Histologically proven (centrally reviewed) high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with SHH or non-SHH/non-WNT (Groups 3 and 4) medulloblastoma, with at least one of the following high risk features: Metastatic disease- Chang Stage M1, M2 and M3, Large cell/anaplastic MB (as defined by WHO criteria 2016 [1]), Patients with MYC or MYCN amplified tumours (unless MYCN amplified non-WNT/non-SHH Group 4 without any other high risk factors), Patients with somatic SHH-TP53 mutant tumours, Patients with significant residual tumour (> 1.5 cm2) following surgical resection of the primary tumour and other biological risk factors (as above)
- Documented negative pregnancy test for female patients of childbearing potential
- Patient agrees to use effective contraception whilst on treatment (patients of childbearing potential)
- Written informed consent from the patient and/or parent/legal guardian
- For Randomisation 2 ONLY: Patient entered into the SIOP-HRMB trial at diagnosis
- For Randomisation 2 ONLY: Patient treated with: Either Arm A (conventional radiotherapy) or Arm B (HART)
- Age at diagnosis ≥3 years. The date of diagnosis is the date on which initial surgery is undertaken
- Submission of biological material, including fresh frozen tumour samples and blood, in accordance with national and international schemes for molecular genetic assessment of biological markers, and for associated biological studies
- No prior treatment for medulloblastoma, other than surgery, with the exception of one cycle of induction chemotherapy with carboplatin and etoposide may be given prior to trial entry and randomisation where there is clinical urgency to start treatment
- Adequate hepatic function defined as: Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, unless the patient is known to have Gilbert’s syndrome OR ALT or AST < 2.5 X ULN for age
- Adequate renal function defined as creatinine < 1.5 x ULN
- Adequate haematological function defined as ANC ≥0.75 x 109/L; platelets ≥ 75 x 109/L, prior to induction chemotherapy
- No significant hearing deficit in at least one ear (significant hearing deficit defined as Chang grade 3 or above)
- Medically fit to receive treatment
Who cannot take part
- Patients with significant residual tumour (> 1.5 cm2) following surgical resection of the primary tumour and no other biological risk factors
- Patients previously treated for a brain tumour or any type of malignant disease
- Medical contraindication to radiotherapy or chemotherapy
- Chang Stage M4 disease
- Known hypersensitivity to any of the treatments or excipients
- Patients with proven or with high likelihood of germline TP53, APC, PTCH1, SUFU, PALB2, BRCA2 gene alteration or any other DNA repair defect
- Females who are pregnant or breastfeeding
- Patients who cannot be regularly followed up due to psychological, social, family, geographical or other issues
- Patients for whom non-compliance with treatment, management guidelines or monitoring is expected
- Non-WNT/non-SHH Group 4 patients with MYCN amplification and no other high-risk factor
- Patients with CTNNB1 mutation positive WNT medulloblastoma irrespective of other risk factors
- Brainstem or embryonal tumours in other sites
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- What type of cancer has the patient been diagnosed with?
- Is this cancer newly diagnosed, or has it come back or not responded to treatment?
- Is the patient pregnant or breastfeeding?
Where in Denmark
Also in 10 other countries, 95 sites
- Aarhus UniversitetshospitalAarhus N, DenmarkTaking people
- RigshospitaletCopenhagen Oe, DenmarkTaking people
- Odense University HospitalOdense C, DenmarkTaking people
About the trial
What the trial wants to find out
To evaluate whether the outcome in children, young people and adults with HR-MB is improved over standard therapy i.e. conventional (once a day) radiotherapy (RT) (standard therapy), for those treated with: hyperfractionated-accelerated radiotherapy (HART), or high-dose therapy (HDT) with thiotepa followed by conventional RT. To evaluate whether the outcome in HR-MB is different for those treated with two different maintenance chemotherapy therapies.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
- Plain-language title
- Tests treatments for high-risk medulloblastoma, a type of brain tumor, in patients over 3Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-510578-25-00, who can take part
- Record updated
- 4 September 2026